Responsible Conduct of Research Providing credible, reliable data (PREP Course #7)
|
|
- Meryl Hall
- 5 years ago
- Views:
Transcription
1 Responsible Conduct of Research Providing credible, reliable data (PREP Course #7) November 15, Community Drive, Goldman Conference Center 9:00-10:30
2 CME Disclosure The North Shore LIJ Health System adheres to the ACCME s Standards for Commercial Support. Any individuals in a position to control the content of a CME activity, including faculty, planners and managers, are required to disclose all financial relationships with commercial interests. All identified potential conflicts of interest are thoroughly vetted by the North Shore LIJ for fair balance and scientific objectivity and to ensure appropriateness of patient care recommendations. Course Director, Kevin Tracey, has disclosed a commercial interest in Setpoint, Inc. as a the cofounder, for stock and consulting support. He has resolved his conflicts by identifying a faculty member to conduct content review of this program who has no conflicts. The Speaker, Cynthia Hahn has nothing to disclose.
3 Agenda/Goals Identify essential study records Describe principles of record keeping and study documentation Illustrate how to maintain records after study closure Identify Research Misconduct vs. Research Non-Compliance Identify and describe reporting mechanisms
4 What is RCR? Responsible Conduct of Research Data Acquisition, Management, Sharing and Ownership Conflict of Interest and Commitment Human Subjects Animal Welfare Research Misconduct Publication Practices and Responsible Authorship Mentor / Trainee Responsibilities Peer Review Collaborative Science
5 Record Keeping/Study Documentation Essential Documents = Research Data: Recorded information necessary to replicate, validate or reconstruct basic or clinical research findings. Financial Regulatory Source Raw Data Analyzed Data
6 Examples of research data can include: Field notes, completed questionnaires Data abstraction forms Laboratory notebooks Patient charts Cage cards Audio tapes, video tapes and electronic data files Gels, blots, spectra, samples, specimens IRB consent forms, research reports, analytical results, analysis Software (computer programs, computer databases and documentation thereof), and records of scientific or technical nature Printouts, computer disks Photographs, slides, negatives, films, scans, images, electrophysiological recordings Data contained in theses and dissertations and all other materials that are relevant to the research or sponsored project Preliminary data in grant applications
7 Why You Need Documentation If it s not documented, it never happened. Reasons: Proof of data collection Provides an audit trail for assessment and verification of study data quality Validates results Evidence of investigator compliance with GCP, regulations, and education requirements Documentation must be maintained regardless of sponsor/funding source
8 Audits and Inspections Who may be looking at your records? External Federal Agencies (e.g. FDA, OHRP, ORI, etc.) State Agencies (NYSDOH, ACS, etc.) Sponsors & monitors Journals Internal IRB & Office of Research Compliance Reviews Research Misconduct Reviews
9 Regulatory Background Federal Regulations: Common Rule (IRB) - 45 CFR 46 FDA regulations - CFR Title 21 Research Misconduct 42 CFR Parts 50 and 93 State Law Institutional & IRB Policies Good Clinical Practice (GCP) Guidelines ICH E6 Essential documents for a study
10 Applicable System Policies Research Data Ownership Maintenance, Storage, and Archiving Clinical Research Data Research Misconduct
11 Research Data Ownership Tangible and intangible research data, inventions, discoveries and devices developed at or through the use of Health System facilities or resources are the property of the Health System. Rights to such property may be transferred to third parties (such as sponsors) only with the express prior written authorization of the Health System. Each PI has principal responsibility for the custody of research data generated in his/her research and clinical studies, whether or not externally sponsored. Identifiable information generated as a result of participation in a clinical research study is Protected Health Information (PHI) under the Health Information Portability and Accountability Act (HIPAA). As a result all applicable health care privacy rules and regulations must be followed.
12 Data Storage, Access, and Management The PI is responsible for the recording, collection, management and retention of research data from any study or project, whether externally or Health System sponsored. These records should include sufficient detail to permit examination and replicate the research or project respond to questions that may result from unintentional error or misinterpretation establish authenticity, and confirm the validity of the conclusions.
13 Lab Notebooks Study title, Investigator s name(s) Study hypothesis, Detailed information on the materials used Sources of the materials Experimental methodology, Statistical treatments, results and conclusions so as to enable replication of the experiments by others at any time and to provide evidence of the creation of inventions. In the event that entry of such research data in an experimental notebook is not possible, the research data shall be secured and explicit instructions as to where the research data can be found (e.g. location of disks, samples, specimens) should be included in the notebook.
14 Good Clinical Practice (GCP) Created to establish a common standard for clinical research practice All studies are held to GCP standards E6: Guidelines for essential documents to be maintained by investigator and sponsor Before, during, and after the trial (see handout) Access ICH GCP E6 Guidance online: RegulatoryInformation/Guidances/ucm pdf
15 Research Data Management The Principal Investigator or must preserve clinical research data for a minimum of seven (7) years for adult subjects and (10) years for pediatric subjects after the final project closeout. When the clinical research study involves a FDA regulated product or device, all clinical research data associated with the trial must be maintained for up to two (2) years after a marketing application is approved; or, if an application is not approved, until two (2) years after shipment and delivery for investigational use is discontinued and FDA has been so notified as required by FDA regulations at 21CFR Where data supports a patent, such data must be retained as long as the patent and any derivative patents are valid;
16 Research Data Management Non-Clinical data must be maintained for at least 3 years after a project is completed. If allegations of scientific misconduct, conflict of interest, or other charges arise, data must be retained until such charges are fully resolved If a student is involved, data must be retained at least until the degree is awarded or the student has unambiguously abandoned the work; and Data must be retained if required by the terms of a grant, contract, Institutional Review Board (IRB) approval or other agreement, or applicable law.
17 Fundamental Elements of Data Quality Is your documentation ALCOA compliant? A Attributable Does the documentation clearly demonstrate: Who created the record and when, What happened, and When it occurred? L Legible Can the information be easily read and understood? C Contemporaneous - Was the information documented with timeliness? Complete Does the documentation include all of the necessary information? O Original Did you maintain the source of the information (see GCP Glossary, Sections 1.51 and 1.52)? A Accurate Does the information represent what actually happened? Adapted from - FDA - GUIDANCE FOR INDUSTRY - COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS - ALCOA
18 Attributable Ensure that the documentation: Clearly describes who the documentation is about. Demonstrates who is involved in the event. Demonstrates the rationale for any revision in the data as well as who made the revision. Legible Ensure that written notes can be easily read and understood. Contemporaneous Ensure that the information was documented with timeliness. When information is added later this weakens its credibility. Complete Ensure the documentation includes all of the necessary information. Original Ensure the source is maintained and available. Accurate Ensure that the documentation captures what actually happened. Explain discrepancies. 18
19 Authorship Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published From: ICMJE: Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Ethical Considerations in the Conduct and Reporting of Research: Authorship and Contributorship
20 Research Misconduct Fabrication, falsification or plagiarism in proposing, performing or reviewing research or in reporting research results. Research misconduct does not include honest error or differences of opinion.
21 Misconduct Fabrication making up data or results and recording and reporting them. This may also include misrepresentation of a researcher s qualifications or ability to perform the research in grant applications or similar submission. Falsification manipulating research materials, equipment or processes, or changing or omitting data or results such that the research is not accurately represented in the research record Plagiarism the appropriation of another person s ideas, processes, results or words without giving appropriate credit.
22 Policy on Misconduct All employees or individuals associated with the North Shore-Long Island Jewish Health System must report observed, suspected, or apparent misconduct in research to the Research Integrity Officer, any Institutional Official, the Office of Research Compliance, or via the Corporate Compliance Help Line Any employee who reports such information will be protected against retaliation for making the report.
23 Research Misconduct Case #1 An investigator is working on a multicenter project with collaborators at 5 other institutions and decides to submit a grant to NIH on a related topic. In his grant application he analyzes partial data from his site that was collected as part of the larger project in support of the new application. Since the data he analyzed was only from his site, he does not discuss the larger project or his collaborators role. Is this research misconduct, why or why not?
24 Case #2 Dr. Clean is conducting an investigator initiated clinical trial. Dr. Smith is a colleague at the same institution who refers patients to Dr. Clean s study and occasionally conducts study related treatments. Dr. Smith is listed on the IRB application on a subinvestigator, but does not participate in protocol development and analysis. When Dr. Clean publishes the study he does not list Dr. Smith as an author. Is this Research Misconduct, why or why not?
25 Case #3 Dr. Brown is working in the lab when he notices that all his samples are being destroyed by the reagent he is using, so he switches the reagent during the next experiment, since this worked better he continues to do it. Is this Research Misconduct, why or why not?
26 Case #4 Dr. Brown is working in the clinic when he notices that it appears all of the subjects on a study are having a skin reaction to a cream being used in testing. The cream itself is not the test article being evaluated in the study so he switches the cream during the next test and the next group of subjects does not have a reaction, since this worked better he continues to do it. Is this Research Misconduct, why or why not?
27 Case #5 Post doc A and Post doc B are working on a project together. During the analysis two data points don t make sense and seem to be errors. Post doc B argues they should just delete the two data points from the analysis, arguing that the samples that day must have been contaminated. Is this Research Misconduct, why or why not?
28 Case #6 An investigator is conducting PCR analysis and the images seem fuzzier than usual. She scans the results into her computer and uses photoshop to change the contrast making the results easier to see. She does not think this should be a problem since she making the change across all the results. Is this Research Misconduct, why or why not?
29 Resources Policies are on Healthport Research Integrity Officer: Dr. Bettie Steinberg Research Compliance: Web-Based Reporting Available 24 hours, 7 days a week Reports Can Be Made Anonymously
PREP Course 24: Defining the Differences between FDA and OHRP regulations. Presented by: Hallie Kassan Dorean Flores Office of the IRB
PREP Course 24: Defining the Differences between FDA and OHRP regulations Presented by: Hallie Kassan Dorean Flores Office of the IRB CME Disclosure Statement The North Shore LIJ Health System adheres
More informationPREP Workshop # 20: Investigational Drug Accountability. Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS
PREP Workshop # 20: Investigational Drug Accountability Presented by: Ji-Eun Kim, Research Pharmacist Investigational Pharmacy Core, CRS CME Disclosure Statement The North Shore LIJ Health System adheres
More informationHuman Research Protection Program Policy
Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationARCHIVING REGULATIONS
The pocket guide to ARCHIVING REGULATIONS How to Maintain Compliance & Drive Efficiencies at Study Closeout Pocket Guide Pocket Guide to Archiving Regulations Being able to easily manage the site archive
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationClinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014
Clinical Trials and the Code of Federal Regulations Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014 The Development of Regulations 1906: Food and Drugs Act
More informationApplicability of US Regulations to Canadian Research
Applicability of US Regulations to Canadian Research Mary Kate Needler Capital District Health Authority Halifax, Nova Scotia, Canada N2 Stakeholder Meeting August 18, 2014 MK s Conventions: 1. US Regulation
More informationROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D
Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Investigational
More informationInvestigator Manual. Human Subjects Protection Program
Human Subjects Protection Program HRP-103, Revised June 1, 2015 HRP-103 06/01/2015 2 of 33 Table of Contents Scope... 3 What is the purpose of this manual?... 3 What is Human Research?... 3 What is the
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationResponsibilities of Investigators for Clinical Trials from Consent to Safety Reporting
Responsibilities of Investigators for Clinical Trials from Consent to Safety Reporting Young-Hak Kim, MD, PhD Department of Medicine,, University of Ulsan College of Medicine, Seoul, Korea Responsibilities
More informationGood Clinical Practice Compliance
Good Clinical Practice Compliance Pharmaceutical Regulatory & Compliance Congress Greg Levine LLP Agenda? GCP compliance rules What is the law? What other (non-binding) standards apply? What are the unwritten
More informationStandard Operating Procedures Guidelines for Good Clinical Practice
SOP # CRSC-105 Effective Date 10-22-2013 Version # 1 Version Date 7-30-2013 Standard Operating Procedures Guidelines for Good Clinical Practice Purpose: This SOP outlines the steps required to follow FDA
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationCOI IN THE MEDIA 10/8/2012 CONFLICT OF INTEREST IN HUMAN SUBJECT RESEARCH HIGH PROFILE CONFLICT OF INTEREST CASES INVOLVING HUMAN SUBJECTS
CONFLICT OF INTEREST IN HUMAN SUBJECT RESEARCH COI IN THE MEDIA Financial conflict of interest frequently appear in the media, but particularly subject to public scrutiny are those high profile adverse
More informationGuidance for Industry - Computerized Systems Used in Clinical Trials
Page 1 of 14 Regulatory Information Computerized Systems Used in Clinical Trials Guidance for Industry - Computerized Systems Used in Clinical Trials
More informationDocument Number: SOP/RAD/SEHSCT/003 Page 1 of 9 Version 2.0
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Archiving Study Documents SOP Number: 3 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date: August
More informationHuman Research Protection Program Plan
Revised January 19, 2018 Table of Contents Human Research Protection Program Plan HRP-101 1/19/2018 2 of 13 Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research...
More informationWCG ACADEMY COURSE OVERVIEW
WCG ACADEMY COURSE OVERVIEW Investigator Course Title Documentation of Informed Consent Duration Ethical Principles Underlying Consent Documentation Long Form Short Form Consent Records Special Considerations
More informationCUSTOMER AND SUPPLIER ROLES AND RESPONSIBILITIES FOR 21 CFR 11 COMPLIANCE ASSESSMENT. 21 CFR Part 11 FAQ. (Frequently Asked Questions)
21 CFR Part 11 FAQ (Frequently Asked Questions) Customer and Supplier Roles and Responsibilities for Assessment of METTLER TOLEDO STARe Software Version 16.00, including: - 21 CFR 11 Compliance software
More informationMedThink SciCom Publication Guidelines
MedThink SciCom Publication Guidelines Mission Statement MedThink SciCom provides medical publication support to pharmaceutical, biotechnology, and medical device clients using specific direction from
More informationHuman Research Protection Program. Investigator Manual
Human Research Protection Program Revised July 7, 2014 HRP-910 7/7/2014 2 of 10 Table of Contents What is the purpose of this manual?... 3 What is Human Research?... 3 What is the Human Research Protection
More informationUNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST
UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST I. PURPOSE To document the policy and procedures used by the University of Tennessee Graduate School
More informationResponsible Conduct of Research (RCR)
Responsible Conduct of Research (RCR) CITI Program s RCR series is composed of six basic courses and one refresher course. Both the basic and refresher courses contain modules that cover core RCR topics.
More informationData Integrity Why is it important? DADM Conference - 22 August 2017
Data Integrity Why is it important? DADM Conference - 22 August 2017 Maibritt Haugaard Møller, System Validation Expert Mette Ravn, Vice President, Data Management, IT and System Validation Overview of
More informationCould Poor Temperature Data Management be Putting Your GxP Facility at Risk for Data Integrity Violations? we prove it.
1 How to Meet New MHRA, FDA and WHO Data Integrity Guidelines WHITE PAPER Could Poor Temperature Data Management be Putting Your GxP Facility at Risk for Data Integrity Violations? we prove it. 2 How to
More informationRESEARCH INTEGRITY AND THE NIH
RESEARCH INTEGRITY AND THE NIH NOVEMBER 9, 2017 PATRICIA VALDEZ, Ph.D. NIH EXTRAMURAL RESEARCH INTEGRITY OFFICER Important Goal of the NIH To exemplify and promote the highest level of scientific integrity,
More informationALCOA AND DATA INTEGRITY: PASTAND FUTURE
ALCOA AND DATA INTEGRITY: PASTAND FUTURE Marina Figini, PCA S.p.A./Aschimfarma Data Integrity: reliability, quality and competitiveness factors of API manufacturers Pavia, 10 Novembre 2017 Good data management
More informationClinical Research: A Multifaceted Discipline
Clinical Research: A Multifaceted Discipline Anuradha Kulkarni a, Arun Bhatt b* a Senior Associate - Medical & Regulatory Affairs, Clininvent Research Pvt Ltd, A-302, Everest Chambers, Marol Naka, Andheri
More informationNew Data Integrity Regulations and Practical Advice for Life Science Laboratories. we prove it.
1 How to Meet New MHRA, FDA, EMA and WHO Data Integrity Guidelines white paper New Data Integrity Regulations and Practical Advice for Life Science Laboratories we prove it. 2 How to Avoid Poor Temperature
More informationInvestigator Conflict of Interest Disclosure Policy for Human Subjects Research
55 Fogg Road South Weymouth Massachusetts 02190-2455 Investigator Conflict of Interest Disclosure Policy for Human Subjects Research PURPOSE OF POLICY Financial or other incentives may negatively impact
More informationSponsor-Investigator Responsibilities In Clinical Trials
In Clinical Trials Margaret Huber, RN, BSN, CHRC Compliance Manager The lecturer has no conflicts for this presentation 9/23/2015 Objectives Define terms sponsor, investigator, and sponsor-investigator.
More information1 The Clinical Research Coordinator (CRC)... 1
TABLE OF CONTENTS Dedication... iii Introduction... xi 1 The Clinical Research Coordinator (CRC)... 1 Role and Responsibilities of the CRC...1 Personality and Skills... 3 Where Do CRCs Work?... 3 CRC Responsibilities...
More informationUNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST
UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST I. PURPOSE To document the policy and procedures used by the University of Tennessee Graduate School
More informationVCU Faculty Held IND and IDE Procedure Handbook
VCU Faculty Held IND and IDE Procedure Handbook Contents A. Introduction... 3 B. Purpose of Institutional Oversight... 3 C. Applicability... 4 D. University Oversight of Clinical Investigations Being Conducted
More informationROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016
UCLA CTSI WELCOME TO ONLINE TRAINING FOR CLINICAL RESEARCH COORDINATORS ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016 Objectives Define the sponsor of a clinical trial and learn
More informationAuthor Statements and Copyright Assignment
Author Statements and Copyright Assignment Manuscript title: Corresponding Author: Before your manuscript (the Work ) can be considered for publication in FPM, each author must attest to his or her authorship
More informationClinical Trial Performance Metrics
Clinical Trial Performance Metrics Clinical trial performance metrics? Data points that provide insight into operational and quality of performance. Objectives of Clinical Trial Performance Metrics The
More informationQuality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework
1 Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework Mandy Morneault Research Compliance Monitor University of Washington Institute of Translational Health
More informationResearch Data Sharing and Security: The Challenges We Face. Jon Mark Hirshon, MD, PhD, MPH Senior Vice-Chair Institutional Review Board
Research Data Sharing and Security: The Challenges We Face Jon Mark Hirshon, MD, PhD, MPH Senior Vice-Chair Institutional Review Board start us off with your involvement with the IRB and the data security/privacy
More informationEthics in the Conduct of Research How It Applies to You. James L. Gulley M.D., Ph.D., F.A.C.P. Chief, GMB, CCR, NCI. IPPCR February 8, 2016
Ethics in the Conduct of Research How It Applies to You James L. Gulley M.D., Ph.D., F.A.C.P. Chief, GMB, CCR, NCI IPPCR February 8, 2016 Scientific Integrity All scientists should be committed to the
More informationSource Documents and Regulatory Binders October 6, 2016
Source Documents and Regulatory Binders October 6, 2016 Lisa Wilson, Regulatory Lead, Clinical Trials Office and Mark Alger, CRC, Clinical Trials Office Essential Documents AKA: the stuff in the Reg Binder
More informationDATA SHARING AGREEMENT
DATA SHARING AGREEMENT Effective Date: This Data Sharing Agreement ( Agreement ) is effective as of the Effective Date between EMD Serono, One Technology Place, Rockland, MA 02370 and Name ( Institution
More informationHUMAN RESEARCH PROTECTION PROGRAM PLAN
HUMAN RESEARCH PROTECTION PROGRAM PLAN HRP 101 June 2017 706-542-3199 irb@uga.edu https://research.uga.edu/hso/ Table of Contents Scope... 2 Purpose... 2 Definitions... 2 Agent... 2 Clinical Trial... 2
More informationORC Sponsor-Investigator IDE Checklist
A sponsor-investigator assumes BOTH investigator and sponsor responsibilities as outlined in the FDA Code of Federal Regulations 21CFR812. This means that such investigators have additional responsibilities.
More informationDeveloping and Implementing Standard Operating Procedures
Developing and Implementing Standard Operating Procedures L A U R A T U T T L E, M A, C C R P U N C T R I A L I N N O V A T I O N U N I T P R O G R A M M A N A G E R NC T R A C S I N S T I T U T E Objectives
More informationConducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
More informationRegulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1
Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1 Phone: 650.691.4400 Fax: 650.691.4410 Email: regulatory.ccsainc.com COMPLIANCE & STANDARDIZATION Rationale for Revision of
More informationGCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:
GCP Refresher and GCP/GCDMP Trends Presented by: in the CTN Denise King, MS, RD, CCRA & Lauren Yesko, BS CTN WEB SEMINAR SERIES: A FORUM TO EXCHANGE RESEARCH KNOWLEDGE Produced by: CTN Training This training
More informationFDA Perspective on International Clinical Trials
FDA Perspective on International Clinical Trials Kassa Ayalew, M.D., M.P.H. Division of Clinical Compliance Evaluation (DCCE) Office of Scientific Investigations (OSI) Center for Drug Evaluation and Research
More informationLessons from Pharmaceutical Laboratory related FDA Warning Letters
Lessons from Pharmaceutical Laboratory related FDA Warning Letters The Agilent Critical Compliance Seminar 2016 Ludwig Huber Ludwig_huber@labcompliance.com Overview FDA Inspections and reports GMP compliance
More informationPOLICY AND PROCEDURE MANUAL. Pennington POLICY NO Origin Date:3/17/2009
POLICY AND PROCEDURE MANUAL Pennington POLICY NO. 106.00 Origin Date:3/17/2009 Biomedical Impacts: All personnel Last revised: 8/21/2014 Subject: Regulatory Compliance Effective: 1/1/2014 Source: Executive
More informationTOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH
Investigators Responsibility #1: Design and Implement Ethical Research Consistent with the Three Ethical Principles Delineated in The Belmont Report. The Belmont Report: Three Basic Ethical Principles:
More informationTitle: IRB Purpose, Principles and Responsibilities Page: 1 of 5
THE NORTH SHORE MEDICAL CENTER Institutional Review Board (IRB) POLICIES AND PROCEDURES IRB Policy Number: 001.2 Title: IRB Purpose, Principles and Responsibilities Page: 1 of 5 Written by: Laura W. Knight,
More informationConflict of Interest Resolution and Disclosure
Conflict of Interest Resolution and Disclosure ISMA CME Training July 28, 2017 Cheryl Stearley, CME Coordinator Indiana State Medical Association Let s Hear What the ACCME Has to Say About Conflicts of
More informationEthics Committees/IRBs Today: Challenges for Efficiency and Quality
Marjorie A. Speers, Ph.D. President and CEO Ethics Committees/IRBs Today: Challenges for Efficiency and Quality Copyright 2013 AAHRPP All rights reserved Goal Clinical Research Globally Access to patients
More informationFacilitating Compliance with 21 CFR Part 11
Facilitating Compliance with 21 CFR Part 11 Michael Hurley Director of Product Management at Complion Disclosure MICHAEL HURLEY Director, Product Management Complion, Inc. I have no relevant financial
More informationSt. Luke s University Health Network
Page 1 of 6 PURPOSE: This standard operating procedure (SOP) serves as a companion to the Standard Operating Procedure for Data Management. The St. Luke s University Health Network (SLUHN) Clinical Trials
More informationHuman Subjects Protection Program Plan
December 1, 2016 HRP-101 12/1/16 2 of 12 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research... 3 Human Research:... 4 Human Subject as Defined
More information10/9/2012. Alicia Joy, IRB. Wednesday October 10, Please be sure to sign in and take copies of each handout.
Wednesday October 10, 2012 Please be sure to sign in and take copies of each handout. 1 Alicia Joy, IRB 2 FH Office of Research Administration Christina Jackson, BSN, RN, CCRC, CHRC 1 ClinicalTrials.gov
More informationPOLICY AND PROCEDURE MANUAL. POLICY NO Origin Date:3/17/2009
POLICY AND PROCEDURE MANUAL Pennington Biomedical POLICY NO. 106.00 Origin Date:3/17/2009 Impacts: All personnel Last revised: 11/20/2015 Subject: Regulatory Compliance Effective: 11/20/2015 Source: Executive
More informationSPAQA GLP Monitoring Authority Roundtable 2017
General Questions 1. Information flow Would it be possible for the GLP notification office to inform SPAQA (vorstand@spaqa.ch) of changes to the Swiss Monitoring Authorities website (e.g. new OECD guidelines,
More informationCODE OF PRACTICE FOR RESEARCH
CODE OF PRACTICE FOR RESEARCH Dr Diana Leighton REF Manager Professor Andy Young Director of Research & Innovation Services Version 1.0 - September 2010 First approved Academic Board 27 September 2010
More informationGCP/Clinical Investigation in Japan
GCP/Clinical Investigation in Japan 27-28 August, 2018 Shinwa Shibata Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency 1 Today s Agenda 1. Japanese-GCP (J-GCP)
More informationServing Patients is a Privilege
Serving Patients is a Privilege This Privilege Comes with Significant Responsibilities Understanding Requirements for Data Integrity How to Develop a Data Integrity Program Including Data Integrity with
More informationData Reliability - Internet
Data Reliability - Internet Wikipedia https://en.wikipedia.org/wiki/reliability_of_wikipedia Others http://www.dailymail.co.uk/health/article- 2639910/Do-NOT-try-diagnose-Wikipedia-90-medicalentries-inaccurate-say-expertsDo.html
More informationGlobal Code of Business Conduct and Ethics
Global Code of Business Conduct and Ethics Message from the chairman Dear Colleagues: The Hay Group Global Code of Business Conduct and Ethics (the Code ) is our company s statement of commitment to the
More informationResearch Involving Human Data or Specimens
Page 1 of 5 Research Involving Human Data or Specimens Introduction: The Office for Human Research Protections has issued guidance on research involving coded private information or human biological specimens.
More informationCode of Good Research Practice
Code of Good Research Practice Updated May 2015 Research and Innovation Support 1 CODE OF GOOD RESEARCH PRACTICE Section 1: The Principles of Good Research Practice The policy and procedures documented
More informationSWOG Subject: Requests for Patient Data Original Release Date: April 2006 Departments Affected: All Revision Date: May 2013
SWOG http://swog.org Page 1 of 5 pages Original Release Date: April 2006 Departments Affected: All Revision Date: May 2013 REQUESTS FOR PATIENT DATA FROM SWOG STUDIES 1. Introduction...1 2. Data Sharing...2
More informationTEESSIDE UNIVERSITY RESEARCH GOVERNANCE FRAMEWORK AND CODE OF PRACTICE FOR ENSURING RESEARCH INTEGRITY
TEESSIDE UNIVERSITY RESEARCH GOVERNANCE FRAMEWORK AND CODE OF PRACTICE FOR ENSURING RESEARCH INTEGRITY 2017-18 CONTENTS 1 INTRODUCTION 3 2 PRINCIPLES OF RESEARCH INTEGRITY 4 3 CODE OF PRACTICE 6 4 DEFINITION
More informationStandard Operating Procedures (SOPs)
Organizational Strategies for Clinical Trials Standard Operating Procedures (SOPs) SUSAN JACKSON, MPA UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE UNC CENTER
More informationGuidelines for Setting Up a Regulatory Binder
Guidelines for Setting Up a Regulatory Binder Prepare for an audit Georgamaly Estronza, MS UPR - Medical Sciences Campus IRB Administrator - Compliance Officer Email: georgamaly.estronza@upr.edu Introduction
More informationHuman Research Participant Protection Program Institutional Review Board (IRB)
Human Research Participant Protection Program Institutional Review Board (IRB) Procedure 1: Determining whether a research activity needs IRB review and approval 1. Subject All research activities that
More informationCollaboration and Efficiency in IRB review of Multi-Site Research
Collaboration and Efficiency in IRB review of Multi-Site Research Human Subject Research Community Conference University of Miami Student Activities Center (SAC) September 11, 2014 Cynthia Hahn VP, Clinical
More informationNorth Shore LIJ Health System, Inc.
North Shore LIJ Health System, Inc. POLICY TITLE: Information System Review and Audit Controls Policy POLICY #: 900.27 System Approval Date: 1/15/2015 ADMINISTRATIVE POLICY AND PROCEDURE MANUAL CATEGORY:
More informationImplementing Good Clinical Practice at an Academic Research Institution
Implementing Good Clinical Practice at an Academic Research Institution Maintaining Essential Documents Partners Human Research Quality Improvement (QI) Program Stephen W. Hayes Outline Significance of
More informationKathy O Kane Kreutzer, M.Ed., Office of Faculty Affairs, School of Medicine March, 2017
SOM Authorship Guidelines, Recent Updates to the ICMJE Uniform Requirements for Scholarship, and the Emerging Role of Social Media in Monitoring Scholarship Kathy O Kane Kreutzer, M.Ed., Office of Faculty
More informationResearch Professionals Network Workshop Series
Research Professionals Network Workshop Series SO YOU THINK YOU KNOW GCP? Mary-Tara Roth Director, CRRO mtroth@bu.edu Gina Daniels Human Research Quality Manager gdaniels@bu.edu What is [ICH] GCP? an
More informationAuthorship. KHALED ALSAKKAF, PhD. Dept. of Community Medicine Faculty of Medicine and Health Sciences University of Aden
Authorship KHALED ALSAKKAF, PhD Dept. of Community Medicine Faculty of Medicine and Health Sciences University of Aden The Author s Seven Deadly Sins Sin Examples 1 Carelessness Citation bias, understatement,
More informationDATA INTEGRITY IN CLINICAL RESEARCH. Singapore Clinical Research Professional (CRP) Forum 25 August 2017
DATA INTEGRITY IN CLINICAL RESEARCH Singapore Clinical Research Professional (CRP) Forum 25 August 2017 Welcome! David W. Fryrear Senior Director R&D Quality Assurance Joined AbbVie in 2013 Responsibilities
More informationIASLC CME Department planners/reviewers/iaslc Ethics Committee/CME Subcommittee et. al. will identify,
DISCLOSURE OF FINANCIAL RELATIONSHIPS RESOLUTION OF CONFLICT OF INTEREST PROCEDURES (COI) CONFLICT OF INTEREST POLICY FOR PROGRAM PLANNERS, SPEAKERS, MODERATORS, REVIEWERS AND AUTHORS OF CONTINUING MEDICAL
More informationEnsure Data Integrity Compliance Enterprise-Wide
Ensure Data Integrity Compliance Enterprise-Wide PharmaQual 360 º Conference February 24, 2017 Chris Wubbolt QACV Consulting, LLC www.qacvconsulting.com 1 Objectives What is data integrity and the definition
More informationCompliance Considerations in Pharmaceutical Product Development
Compliance Considerations in Pharmaceutical Product Development John C. (Jack) Garvey, Esq. THE WEINBERG GROUP INC. PRINCETON, NJ Compliance in Drug Development The Drug Development Challenge A Sampling
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More informationSource And Regulatory Documentation for DMID Clinical Studies
Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in
More informationStandard Operating Procedure for Archiving
Standard Operating Procedure for Archiving SOP name: NWORTH07/19 archiving Version 2 Authorship Team: Angela Gliddon & Rhiannon Whitaker Meeting date reviewed 16 th April 2008 Designated NWORTH member
More informationViews of a Clinical Study Report
Out-of-(CSR)-Body Experiences Tips on Assembling Appendices, Datasets, and CRFs Susan C Sisk, PhD, RAC 1 Views of a Clinical Study Report OR Photos courtesy of Leigh Vaughan and RAPS, 2008 2 Topics Process
More informationIASLC CME Department planners/reviewers/iaslc Ethics Committee/CME Subcommittee et. al. will identify,
DISCLOSURE OF FINANCIAL RELATIONSHIPS RESOLUTION OF CONFLICT OF INTEREST PROCEDURES (COI) CONFLICT OF INTEREST POLICY FOR PROGRAM PLANNERS, SPEAKERS, MODERATORS, REVIEWERS AND AUTHORS OF CONTINUING MEDICAL
More informationGCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018
1 GCP INSPECTION FINDINGS Singapore Research Ethics Conference 2018 Sumitra Sachidanandan GCP Inspection Consultant Clinical Trials Branch Health Products Regulation Group Health Sciences Authority Singapore
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More informationDetails: Approval: Distribution & Storage:
Details: Author: Neville Young Quality Assurance Manager SOP Pages: Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person approving
More informationOverview of Good Publication Practice Guidelines, including GPP3: Why should medical writers care?
Overview of Good Publication Practice Guidelines, including GPP3: Why should medical writers care? Teresa Peña, PhD Head, Medical Publications Bristol-Myers Squibb ISMPP Board Chair & GPP3 Author San Antonio,
More information2 : self-directing freedom and especially moral independence 3 : a self-governing state
A Adverse Effect Adverse Event AE Amendment Approve Approve Pending Assent Assurance Authorization Autonomy Unanticipated problem or unfavorable symptom or disease occurring during a clinical study, though
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional
More informationClarity CDS since version 7.2 supportive tools for compliance with Title 21 CFR Part 11, EudraLex Chapter 4, Annex 11 and other similar legislation
Clarity CDS since version 7.2 supportive tools for compliance with Title 21 CFR Part 11, EudraLex Chapter 4, Annex 11 and other similar legislation Datasheet Introduction US Part 11 in Title 21 of Code
More informationHuman Subjects Research Policy Update. Naomi Coll Director of Research Policy and Compliance
Human Subjects Research Policy Update Naomi Coll Director of Research Policy and Compliance Major Policy Updates 1. Activities that meet the HHS or FDA definition of human subjects research are subject
More informationGood Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations
Good Clinical Practice (GCP): how does a laboratory that supports a clinical trial ensure compliance with these Regulations 9th edition of Synevo Clinical Research Symposium. 17 th November 2017 Bucharest.
More informationHuman Research Protection Program. Plan
Human Research Protection Program Plan Revised September 6, 2017 HRP-101 9/6/17 2 of 13 Table of Contents Scope... 3 Purpose... 3 Definitions... 3 Agent... 3 Clinical Trial... 3 Engaged in Human Research...
More information